



The 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)

October 24-27, 2024, Berlin, Germany

costem.cme-congresses.com

Faculty Disclosures Report - as of September 2, 2024

The 2024 COSTEM Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COSTEM participants. In doing so, the 2024 COSTEM Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The 2024 COSTEM Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The 2024 COSTEM Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the 2024 COSTEM Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the 2024 COSTEM Congress of CME based on the CME providers of the Congress. All COSTEM Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The 2024 COSTEM Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

COSTEM Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium	H
Receipt of consultation / advisory board / employment fees:	C
Other Financial or Material Support	F
Speaker’s Bureau	S
Research funding	R
Employee	E
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Emanuele Angelucci, Italy

H Vertex, BMS
C Menarini, Regeneron
S Gilead

Francis Ayuk, Germany

H Kite/Gilead, MNK/Therakos, BMS/Celgene, medac, Takeda, AbbVie, Novartis, Miltenyi Biomedicine, Janssen
R MNK/Therakos

Peter Bader, Germany

H, R medac
Other *Patent, royalties medac for MSC*

André Baruchel, France

H Servier, Amgen
C Astra Zeneca, Jazz
R Servier

Ali Bazarbachi, Lebanon

H Roche, Sanofi, Janssen, Takeda, Amgen, Adienne
C Roche, Janssen, Caribou, Roche
R Roche, Janssen, Pfizer

Francesca Bonifazi, Italy

C Novartis, Kite, BMS, Pfizer, Neovii, Sanofi, Takeda, Amgen, Janssen, Jazz, medac

Lars Bullinger, Germany

H AbbVie, Amgen, Astellas, BMS, Celgene, Daiichi Sankyo, Janssen, Jazz, Novartis, Pfizer, Sanofi
C AbbVie, BMS, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz, Novartis, Pfizer, Servier
R Bayer, Jazz

Andreas Burchert, Germany

H Astellas, Incyte
R Incyte

Claudio Cerchione, Italy

C,S AbbVie, Amgen, Astellas, BeiGene, BMS, Curis, Glycomimetics, GSK, Immunogen, Janssen, Jazz, Karyopharm, Menarini-Stemline, Oncopeptides, Pfizer, Sanofi, Servier, Skyline DX, Takeda

Corey Cutler, USA

C Sanofi, CSL Behring, Incyte

Rafael de la Cámara, Spain

H Gilead
C MSD, Moderna, Astra Zeneca
S MSD

Marcos de Lima, USA

C AbbVie, Autolus, Cellenkos, Pfizer, Priothera
R Miltenyi Biotec



The 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)

October 24-27, 2024, Berlin, Germany

costem.cme-congresses.com

Fernando Barroso Duarte, Brazil

Nothing to declare

Carlo Dufour, Italy

C Pfizer, SOBI, Biocryst Pharma, Rocket Pharma, Amgen, Novartis, Ono

Britta Eiz-Vesper, Germany

Nothing to declare

Nico Gagelmann, Germany

C BMS, MorphoSys, Stemline

S BMS, Stemline, Pfizer, Neovii, Janssen

Sebastian Giebel, Poland

H,C,S Amgen, Pfizer

Nicola Gökbuget, Germany

C,S Amgen, Astra Zeneca, Autolus, Celgene, Clinigen, Gilead, Incyte, Jazz, Novartis, Pfizer, Sanofi, Servier

R Amgen, Clinigen, Incyte, Jazz, Novartis, Pfizer, Servier

Raffaella Greco, Italy

H Biotest, Pfizer, medac, Qiagen, Magenta

C Pfizer

Hildegard Greinix, Austria

C Therakos, Novartis, Gilead, BMS, Sanofi, Takeda

S Therakos, Stemline, Novartis, Gilead, Sanofi

Carmelo Gurnari, Italy

Nothing to declare

Krzysztof Kalwak, Poland

Nothing to declare

Guenther Koehne, USA

Nothing to declare

Nicolaus Kröger, Germany

R DKMS, Novartis

C Neovii, Astellas, Alexion, BMS, Kite

S Neovii, Sanofi, BMS, Alexion, Pierre Fabre, Novartis

Stephanie Lee, USA

H Mallinckrodt, Equillium, Astra Zeneca, Novartis, Incyte, Pfizer, Sanofi

C Mallinckrodt, Equillium, Novartis, Incyte, Sanofi

R Astra Zeneca, Incyte, Pfizer, Sanofi

Suzanne Lentzsch, USA

C Pfizer, Janssen, GSK, Sanofi, BMS, Karyopharm

R Sanofi, Zentaris

S Regeneron, PeerView, Clinical Care Options, Medscape, Springer Healthcare

Other *Data Safety Monitoring Board – Regeneron, Janssen, BMS; Royalties, Patents – Caelum Bioscience*



The 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)

October 24-27, 2024, Berlin, Germany

costem.cme-congresses.com

Franco Locatelli, Italy

C Amgen, Neovii, Novartis, Sanofi, Miltenyi, Pfizer

S Bellicum Pharma, Amgen, Neovii, Novartis, Miltenyi, medac, Gilead, Takeda, bluebird bio, SOBI, Jazz

Other *Clinical trials – Bellicum Pharma, Amgen, Novartis, Takeda, bluebird bio, SOBI, Jazz, Vertex, GSK*

Peihua Lu, China

Nothing to declare

Leo Luznik, USA

Nothing to declare

Markus Mapara, USA

C Ossiumhealth, CRISPR/VTX, bluebird bio

Donal McLornan, UK

H GSK

C GSK, Novartis

S Novartis

Maximilian Merz, Germany

H Janssen, BMS, AbbVie, Menarini Stemline

C Janssen, BMS, AbbVie, Menarini Stemline, Pfizer

R Janssen, SpringWorks, Roche/GenenTech

S Janssen

Lori Muffly, USA

C Astellas, Vor, Cargo, Kite, Pfizer, Autolus

R Vor, Wugen, Jasper, Adaptive

Fabian Müller, Germany

H Astra Zeneca, AbbVie, Beigene, BMS, Janssen, Kite/Gilead, Miltenyi, Novartis, SOBI, Takeda

C Astra Zeneca, ArgoBio, BMS, CRISPR, Janssen, Kite/Gilead, Miltenyi, Novartis, SOBI

R Astra Zeneca, Kite/Gilead

Arnon Nagler, Israel

Nothing to declare

Alessandro Rambaldi, Italy

C Novartis, Omeros, Roche, Amgen, Kite/Gilead, Janssen, Pfizer, Jazz, Pierre Fabre

Antonio Maria Risitano, Italy

C Novartis, Roche, Omeros

S Pfizer, Novartis, SOBI, Alexion

Thomas Schroeder, Germany

H,C AbbVie

Avichai Shimoni, Israel

Nothing to declare

Roni Shouval, USA

Nothing to declare



The 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)

October 24-27, 2024, Berlin, Germany

costem.cme-congresses.com

Robert Soiffer, USA

C Astellas, Amgen, Smart Immune, Neovii, Vor, Jasper, BMS

Matthias Stelljes, Germany

H Pfizer, Amgen, BMS

C Pfizer, Amgen, MSD, BMS

R Pfizer

S Pfizer, Jazz, medac

Jan Styczynski, Poland

H MSD, Novartis, Gilead, Astra Zeneca

C Novartis, Astra Zeneca, Chiesi, Pfizer, Moderna

S MSD, Novartis, Astra Zeneca, Gilead, Sanofi

Anna Sureda, Spain

H AbbVie, GenMab, Roche, Regeneron, Takeda, MSD, BMS/Celgene, Inctye, Jazz, Menarini, Gilead Kite

C AbbVie, GenMab, Roche, Regeneron, Takeda, MSD, BMS/Celgene, Inctye, Jazz, Autolus, Caribou, Gilead Kite, Novartis

R,S Takeda

Takanori Teshima, Japan

H Astellas, AbbVie, Nippon Shinyaku, Kyowa Kirin, Novartis, BMS, Chugai, MSD, Sumitomo Pharma, Janssen

C Kyowa Kirin, Nippon Shinyaku, Meiji Seika Pharma, Otsuka

R Astellas, Fuji Pharma, Nippon Shinyaku, Kyowa Kirin, Eisai, Sumitomo Pharma, Shiongi, Ono, Asahi Kasei Pharma, Otsuka, Chugai